Clinical Trial: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
Study Status: Completed
Recruit Status: RECRUITING
Condition: Ulcerative Colitis
Study Type: INTERVENTIONAL
Official Title: A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative Colitis
Brief Summary:
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis.The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo.The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Read more